Guidance

Pneumococcal polysaccharide vaccine: patient group direction template

PGD template to support the national pneumococcal polysaccharide vaccine (PPV) vaccination programme.

Applies to England

Documents

Pneumococcal polysaccharide vaccine (PPV): patient group direction (PGD) template

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template supports the administration of 23-valent pneumococcal polysaccharide vaccine (PPV) to individuals from 65 years of age, and individuals from 2 years of age in a clinical risk group, in accordance with the national immunisation programme; and supports PPV administration to close contacts in accordance with UK guidelines for the public health management of clusters of serious pneumococcal disease in closed settings.

The PPV PGD version 5.00 is valid from 1 September 2024 to 1 March 2027.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Updates to this page

Published 13 September 2016
Last updated 31 July 2024 + show all updates
  1. Added version 5, see page 3 for change history.

  2. Added version 4 - see page 2 for change history.

  3. Updated template (V03.00) following routine review.

  4. Added routine PGD update with indication for close contacts in a closed setting.

  5. First published.

Sign up for emails or print this page